Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
JA3yK71puVPjRX55
